Licensed from one of TAP’s parent companies, Takeda Pharmaceuticals, TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.
“Phase I clinical trial data have shown that TAK-390MR may have the potential to bring additional benefits to patients who suffer from acid related diseases,” said Dr Francois-Xavier Frapaise, vice president of R&D for TAP. “We are enthusiastic to initiate a comprehensive phase III clinical program involving more than 5,000 patients.”
In addition to the development of TAK-390MR, TAP will be focusing development efforts on other investigational products for gastroenterological conditions.
TAP Pharmaceutical Products, located in Lake Forest, Illinois, is a joint venture between Abbott and Takeda Pharmaceutical Company, of Osaka, Japan.